Ocugen Files Q1 2025 10-Q Report
Ticker: OCGN · Form: 10-Q · Filed: May 9, 2025 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Ocugen's Q1 2025 10-Q is in. Check financials and biz updates.
AI Summary
Ocugen, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Key financial figures and operational highlights for the first quarter of 2025 are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial health and operational status of Ocugen, Inc., crucial for understanding its current trajectory and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Ocugen faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Period End Date (The 10-Q covers financial information up to this date.)
- 2025-01-01 — Period Start Date (The 10-Q covers financial information from this date.)
Key Players & Entities
- Ocugen, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250509 (date) — Filing date
- 11 Great Valley Parkway, Malvern, PA 19355 (address) — Company's business and mailing address
FAQ
What were Ocugen's key financial results for the first quarter of 2025?
The filing covers the period ending March 31, 2025, and details financial results for Q1 2025, though specific dollar amounts for revenue, expenses, or net income are not provided in this header information.
What is Ocugen's primary business focus as indicated by its SIC code?
Ocugen's Standard Industrial Classification (SIC) code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)', indicating a focus on developing biological products.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 9, 2025.
What is the company's fiscal year end?
Ocugen's fiscal year ends on December 31st.
Has Ocugen undergone any previous name changes?
Yes, Ocugen was formerly known as Histogenics Corp, with a date of name change on August 10, 2006.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Ocugen, Inc. (OCGN).